Abstracts tagged "DMARDs and combination therapies"

Abstract Number: 1055 • 2013 ACR/ARHP Annual Meeting
Discontinuation Rates In Patients With RA Of Triple Disease Modifying Antirheumatic Therapy
Sofia Pedro¹, Frederick Wolfe¹, Hawre Jalal² and Kaleb Michaud³, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²Health Polisy and Management, University of Minnesota, Minneapolis, MN, ³Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Drug discontinuation rates are measures of effectiveness and are needed in health economic models. While a recent RCT demonstrated statistical equivalence of efficacy with…
Abstract Number: 1300 • 2012 ACR/ARHP Annual Meeting
Characteristics Associated with Biologic Initiation As Monotherapy Versus Combination Therapy in Patients with Rheumatoid Arthritis (RA) in a US Registry Population
Dimitrios A. Pappas¹, George W. Reed², Katherine C. Saunders³, Ani John⁴, Ashwini Shewede⁴, Jenny Devenport⁵, Jeffrey D. Greenberg⁶ and Joel M. Kremer⁷, ¹Columbia University, New York, NY, ²University of Massachusetts Medical School, Worcester, MA, ³Corrona, LLC., Southborough, MA, ⁴Genentech Inc., South San Francisco, CA, ⁵Genentech, South San Francisco, CA, ⁶Rheumatology, NYU Hospital for Joint Diseases, New York, NY, ⁷Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Approximately one-third of RA patients were prescribed biologic (Bio) monotherapy (MT) i.e. without concomitant disease-modifying anti-rheumatic drugs (DMARD) (Yazici et al., 2008). The purpose…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].